Life sciences news.

Explore the latest global highlights at the intersection of life sciences and digital innovation.

A vial of proteomics sample on a laboratory bench with equipment in the background.

Apr 15, 2026

Is Thermo Fisher (TMO) Quietly Rewiring Its AI Strategy Through New Data and Proteomics Alliances?

Thermo Fisher Scientific is strategically enhancing its AI capabilities through new partnerships focused on data and proteomics.In April 2026, Thermo Fisher announced collaborations with HealthVerity and Precision Health Research Singapore, aiming to integrate advanced data analytics and proteomics into clinical workflows. These partnerships are designed to enhance Thermo Fisher's position in clinical development and biomanufacturing by leveraging extensive healthcare datasets and innovative ser
A minimalist illustration of a pill and a molecule representing drug development.

Apr 15, 2026

Big Pharma races to lock in AI deals to accelerate drug breakthroughs

Big Pharma is increasingly collaborating with AI technology firms to enhance drug development processes.Recently, Novo Nordisk announced its partnership with OpenAI, aiming to leverage AI for drug research and development, manufacturing, and commercial operations. The integration of advanced AI is expected to facilitate the analysis of complex datasets, identify new drug candidates, and expedite the transition from research to patient access. Additionally, OpenAI will assist Novo in enhancing it
A minimalist illustration of an x-ray machine on a dark background.

Apr 15, 2026

Siemens Healthineers stock (DE000SHL1006): Is advanced imaging strength enough to drive U.S. investo

Siemens Healthineers is strategically positioned to leverage its advanced imaging capabilities amid increasing healthcare demands in the U.S. market.The company operates through three main segments: Imaging, Diagnostics, and Advanced Therapies, with Imaging being the largest revenue generator. This segment benefits from recurring service contracts that provide stable income, insulating the business from fluctuations in equipment sales. The Diagnostics division addresses the continuous need for t
A stack of medical files on a desk with a pen, in a dimly lit office setting.

Apr 15, 2026

Healthcare AI Company Synthpop Raises $15 Million to Automate Administrative Workflows

Synthpop, a healthcare AI startup, has successfully raised $15 million in Series A funding to enhance its automation capabilities for administrative workflows in the healthcare sector.The funding round, led by Ansa Capital, brings Synthpop's total funding to $23 million. The company specializes in using artificial intelligence to streamline various healthcare business processes, effectively automating up to 80% of tasks such as prior authorizations and claims processing. This integration allows
Fetal heart monitor with electrode pads in a clinical setting

Apr 15, 2026

Wavelet Aims To Transform Fetal Heart Monitoring With AI, Non-Invasive EEG Tech

Wavelet Medical is innovating fetal monitoring through an AI-driven, non-invasive EEG platform designed to identify fetal brain distress.The company aims to enhance current fetal monitoring practices by utilizing advanced technology that allows for safer and more effective assessments of fetal health. This non-invasive approach could significantly reduce risks associated with traditional monitoring methods, offering a promising alternative for expectant parents and healthcare providers.By levera
A stethoscope on a medical chart in a dimly lit examination room

Apr 15, 2026

CompuGroup Medical stock (DE000A288904): Why its healthcare IT dominance matters more now for global

CompuGroup Medical (ISIN: DE000A288904) is positioned as a key player in the rapidly evolving healthcare IT landscape, making it an attractive investment for those seeking stability and growth in this sector. As the global demand for digital health solutions rises, the company's stronghold in Europe allows it to benefit from the ongoing shift towards electronic health records (EHR) and telemedicine.CompuGroup Medical excels in providing software that enhances the efficiency of healthcare provide
Silhouette of a human body with a drug compound overlay

Apr 14, 2026

Simulations Plus stock (US82834F1012): Is its pharma simulation edge strong enough to unlock new ups

Simulations Plus is carving out a significant niche in the pharmaceutical simulation market, leveraging its technology to meet the growing demand for efficient drug discovery processes amidst an AI-driven landscape.The company specializes in physiologically based pharmacokinetic (PBPK) modeling software, which allows researchers to simulate drug behavior in the human body. This approach aims to address the high failure rates associated with clinical trials, which can exceed 90% for new compounds
A vial of medication on a lab bench in a pharmaceutical lab

Apr 14, 2026

Novo Nordisk taps OpenAI to accelerate AI push across drug development

Novo Nordisk has partnered with OpenAI to enhance its drug development processes by integrating artificial intelligence across various operational areas, including drug discovery and manufacturing. This collaboration aims to improve efficiency and productivity, particularly in the competitive obesity drug market, which has a projected worth exceeding $100 billion in annual revenue over the next decade.The partnership will initiate pilot programs that utilize OpenAI’s technology to analyze comple
Flat illustration of a virtual twin concept in product design

Apr 14, 2026

Dassault Systèmes SE stock (FR0014003TT8): Why its software dominance now matters more for U.S. inv

As industries increasingly adopt digital twins and AI-driven design, Dassault Systèmes' 3DEXPERIENCE platform emerges as a pivotal tool, particularly for investors in the U.S. and other English-speaking markets.Dassault Systèmes SE is positioned at the forefront of industrial software, providing essential virtual twin technology that reshapes product design and manufacturing processes. Its 3DEXPERIENCE platform integrates various stages of product development, making it vital for sectors such as
A petri dish with cultured cells and a research notebook in a dimly lit lab.

Apr 14, 2026

Building biology-native data infrastructure for the AI era

The landscape of drug development is rapidly evolving with the integration of AI technologies, aiming to streamline the lengthy and costly process of turning biological hypotheses into clinical candidates.The traditional approach to drug development has been characterized by significant time delays and high failure rates, with nearly 90% of drugs failing in clinical trials. The escalating costs associated with research and development, which double approximately every nine years, highlight the u